Dynamic Therapeutics, a spin-out from the University of Bristol, has recently been honored with a prestigious Blavatnik Prize from venture capital firm QantX. This recognition comes as a result of their groundbreaking U-RHYTHM technology, capable of collecting up to 72 samples over a 24-hour period to gather vital data on hormone production.
The U-RHYTHM technology works by monitoring the patterns of biologically active molecules within tissues and tracking how they evolve over time. This information can then be analyzed to pinpoint any disruptions that could affect health, detecting issues at their earliest stages.
Conventional methods for diagnosing hormone-related conditions can be complex due to the significant fluctuations in hormone levels throughout the day and between individuals. Dynamic Therapeutics aims to set a new standard for time-based hormone measurement, enhancing the accuracy of diagnoses and treatments for patients with conditions such as Type 1 diabetes and hypertension.
In addition to its impact on diagnosing and managing various health conditions, the U-RHYTHM technology has potential applications in fertility monitoring, post-operative care, drug development, and pediatric care without the need for frequent blood sampling.
CEO of QantX, Richard Haycock, expressed the importance of dynamic health information and the potential of U-RHYTHM in revolutionizing healthcare. Professor Stafford Lightman, co-founder of Dynamic Therapeutics, highlighted the positive response to their trials and emphasized their commitment to commercialize the technology in the near future.
Dynamic Therapeutics is moving forward with further trials of the U-RHYTHM technology in collaboration with research institutions globally, following positive feedback and recognition in the scientific community for its clinical applications and potential to redefine disease states.
